



PEER-REVIEW REPORT

Name of journal: World Journal of Transplantation

Manuscript NO: 59339

Title: Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients

Reviewer's code: 03293239

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Spain

Author's Country/Territory: United States

Manuscript submission date: 2020-09-06

Reviewer chosen by: Xi-Fang Chen (Quit in 2021)

Reviewer accepted review: 2020-10-12 11:54

Reviewer performed review: 2020-10-26 18:10

Review time: 14 Days and 6 Hours

Scientific quality	<input checked="" type="checkbox"/> Grade A: Excellent [] Grade B: Very good [] Grade C: Good [] Grade D: Fair [] Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing [] Grade B: Minor language polishing [] Grade C: A great deal of language polishing [] Grade D: Rejection
Conclusion	<input checked="" type="checkbox"/> Accept (High priority) [] Accept (General priority) [] Minor revision [] Major revision [] Rejection
Re-review	<input checked="" type="checkbox"/> Yes [] No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous [] Onymous Conflicts-of-Interest: [] Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA

Telephone: +1-925-399-1568

E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Very interesting analysis of prediction of cancer using a new model. Just add the limitation of a retrospective design of the paper.



PEER-REVIEW REPORT

Name of journal: World Journal of Transplantation

Manuscript NO: 59339

Title: Risk prediction model for cutaneous squamous cell carcinoma in adult cardiac allograft recipients

Reviewer's code: 03650328

Position: Editorial Board

Academic degree: FRCP (C), MD, MSc

Professional title: Assistant Professor

Reviewer's Country/Territory: Canada

Author's Country/Territory: United States

Manuscript submission date: 2020-09-06

Reviewer chosen by: Xi-Fang Chen (Quit in 2021)

Reviewer accepted review: 2020-10-29 14:19

Reviewer performed review: 2020-11-05 03:45

Review time: 6 Days and 13 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input checked="" type="checkbox"/> Grade A: Priority publishing <input type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No



**Baishideng
Publishing
Group**

7041 Koll Center Parkway, Suite
160, Pleasanton, CA 94566, USA
Telephone: +1-925-399-1568
E-mail: bpgoffice@wjgnet.com
https://www.wjgnet.com

SPECIFIC COMMENTS TO AUTHORS

Nair et al. retrospectively analyzed the UNOS registry to identify risk factors associated with the development of squamous cell carcinoma in adult heart transplant recipients. They identified 8 risk factors in multivariate analysis and used these to construct a risk score which was validated in a subset of patients from the same data source. Overall, the manuscript is well-written and the conclusions are clear. Comments: 1. In the Abstract, clarify the source of the validation data set and the distribution of the derivation and validation cohorts. 2. How were the patients divided into the derivation and validation cohorts? Randomly allocated? 3. What is the point of including drugs that are no longer used (OKT3 and daclizumab) in the analysis? If OKT3 and daclizumab were omitted from the analysis, I wonder if ATGAM or basiliximab would emerge as risk factors, which would be a more clinically-relevant result... 4. The presence of coronary artery disease and CHD are likely surrogates for patient age. 5. In Table 5, should the high-risk group be compared to the low- and very-low risk groups? 6. An important limitation is the use of a single data source for the derivation and the validation cohorts and it should be explicitly stated that these findings will need to be replicated in a separate patient population and ideally prospectively. 7. In the title, I would specify that adult cardiac allograft recipients were studied.